Digestive Hormones Research Articles

Modulation of Postprandial Plasma Concentrations of Digestive Hormones and Gut Microbiota by Foods Containing Oat ß-Glucans in Healthy Volunteers.

Cereal β-glucans are beneficial health ingredients that reduce cholesterolemia and postprandial glycaemia. However, their impact on digestive hormones and gut microbiota is not yet fully established. Two randomized, double-blind, controlled studies were conducted. In the first study, 14 subjects ingested a breakfast with or without β-glucan from oats (5.2 g). Compared to the control, β-glucan increased orocecal transit time (p = 0.028) and decreased mean appetite score (p = 0.014) and postprandial plasma ghrelin (p = 0.030), C-peptide (p = 0.001), insulin (p = 0.06), and glucose (p = 0.0006). β-glucan increased plasma GIP (p = 0.035) and PP (p = 0.018) without affecting leptin, GLP-1, PYY, glucagon, amylin, or 7α-hydroxy-4-cholesten-3-one, a biomarker of bile acid synthesis. In the second study, 32 subjects were distributed into 2 groups to ingest daily foods with (3 g/day) or without β-glucan for 3 weeks; stools were collected before/after treatment. No changes in fecal microbiota composition/diversity (deep sequencing) were detected with β-glucans. These results indicate that acute intake of 5 g β-glucan slows transit time and decreases hunger sensation and postprandial glycaemia without affecting bile-acid synthesis, these changes being associated with decreased plasma insulin, C-peptide, and ghrelin, and increased plasma GIP and PP. However, regular daily intake of 3 g β-glucan is not sufficient to have an effect on fecal microbiota composition.

Pendampingan Pembuatan Makanan Pendamping ASI Menggunakan Sumber Air Minum Rumahan Pada Ibu Di Klinik AZ-ZAHRA Tahun 2022

The purpose of community service activities is in the form of Assistance in Making Complementary Food for Breast Milk Using Home Drinking Resources for Mothers at AZ-ZAHRA Clinic in 2022. This research method This study uses a descriptive research method that deals with independent variables without making comparisons or connecting with other variables and does not intend to test hypotheses but only describes the description of MPASI consumption patterns such as the type of food given, treatment of home drinking water sources, the use of drinking water sources for MPASI, the frequency of MPASI consumption and the level of nutritional adequacy of MPASI in infants aged 12-24 month at AZ-ZAHRA Clinic. The results of this study The selection of water must also follow the hygiene standards of home drinking water sources. Unlike teenagers and adults, babies have lower immunity. This happens because the immune system in the baby's body is not perfect. The same goes for the digestive system. In addition to incomplete digestive hormones and enzymes, the gaps in the baby's gastrointestinal tract are also still loose

AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE

Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.

Transversal gene expression panel to evaluate intestinal health in broiler chickens in different challenging conditions

There is a high interest on gut health in poultry with special focus on consequences of the intestinal diseases, such as coccidiosis and C. perfringens-induced necrotic enteritis (NE). We developed a custom gene expression panel, which could provide a snapshot of gene expression variation under challenging conditions. Ileum gene expression studies were performed through high throughput reverse transcription quantitative real-time polymerase chain reaction. A deep review on the bibliography was done and genes related to intestinal health were selected for barrier function, immune response, oxidation, digestive hormones, nutrient transport, and metabolism. The panel was firstly tested by using a nutritional/Clostridium perfringens model of intestinal barrier failure (induced using commercial reused litter and wheat-based diets without exogenous supplementation of enzymes) and the consistency of results was evaluated by another experiment under a coccidiosis challenge (orally gavaged with a commercial coccidiosis vaccine, 90× vaccine dose). Growth traits and intestinal morphological analysis were performed to check the gut barrier failure occurrence. Results of ileum gene expression showed a higher expression in genes involved in barrier function and nutrient transport in chickens raised in healthy conditions, while genes involved in immune response presented higher expression in C.perfringens-challenged birds. On the other hand, the Eimeria challenge also altered the expression of genes related to barrier function and metabolism, and increased the expression of genes related to immune response and oxidative stress. The panel developed in the current study gives us an overview of genes and pathways involved in broiler response to pathogen challenge. It also allows us to deep into the study of differences in gene expression pattern and magnitude of responses under either a coccidial vaccine or a NE.

Ameliorative Effect of Ananas comosus on Cobalt Chloride-Induced Hypoxia in Caco2 cells via HIF-1α, GLUT 1, VEGF, ANG and FGF.

In the present study, protective effects of Ananas comosus i.e., pineapple pulp (PA) against cobalt chloride (CoCl2)‑induced hypoxia in Caco-2cells were evaluated. PA reduces levels of lipid peroxidation, reactive oxygen and nitrogen species. It was proved to be cytoprotective and increased anti-oxidant activity against CoCl2-induced hypoxia. The inference drawn from this experiment was CoCl2-induced hypoxia that regulates hypoxia-inducible factor-1 (HIF-1), a transcription factor. It was also confirmed that PA pre-treatment inhibited the expression of HIF-1α, thereby downregulating the hypoxia-associated gene/protein expressions such as GLUT-1, VEGF, ANG and FGF. Finally, supplementation of PA could help in snow-balling the digestive hormones like leptin and CCK in hypoxic conditions. Therefore, this report provides substantial proof of reducing the hypoxia-induced loss of appetite at high-altitude environments. Graphical Abstract.

International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

The calcium-sensing receptor (CaSR) is a class C G protein-coupled receptor that responds to multiple endogenous agonists and allosteric modulators, including divalent and trivalent cations, L-amino acids, γ-glutamyl peptides, polyamines, polycationic peptides, and protons. The CaSR plays a critical role in extracellular calcium (Ca2+ o) homeostasis, as demonstrated by the many naturally occurring mutations in the CaSR or its signaling partners that cause Ca2+ o homeostasis disorders. However, CaSR tissue expression in mammals is broad and includes tissues unrelated to Ca2+ o homeostasis, in which it, for example, regulates the secretion of digestive hormones, airway constriction, cardiovascular effects, cellular differentiation, and proliferation. Thus, although the CaSR is targeted clinically by the positive allosteric modulators (PAMs) cinacalcet, evocalcet, and etelcalcetide in hyperparathyroidism, it is also a putative therapeutic target in diabetes, asthma, cardiovascular disease, and cancer. The CaSR is somewhat unique in possessing multiple ligand binding sites, including at least five putative sites for the "orthosteric" agonist Ca2+ o, an allosteric site for endogenous L-amino acids, two further allosteric sites for small molecules and the peptide PAM, etelcalcetide, and additional sites for other cations and anions. The CaSR is promiscuous in its G protein-coupling preferences, and signals via Gq/11, Gi/o, potentially G12/13, and even Gs in some cell types. Not surprisingly, the CaSR is subject to biased agonism, in which distinct ligands preferentially stimulate a subset of the CaSR's possible signaling responses, to the exclusion of others. The CaSR thus serves as a model receptor to study natural bias and allostery. SIGNIFICANCE STATEMENT: The calcium-sensing receptor (CaSR) is a complex G protein-coupled receptor that possesses multiple orthosteric and allosteric binding sites, is subject to biased signaling via several different G proteins, and has numerous (patho)physiological roles. Understanding the complexities of CaSR structure, function, and biology will aid future drug discovery efforts seeking to target this receptor for a diversity of diseases. This review summarizes what is known to date regarding key structural, pharmacological, and physiological features of the CaSR.

Nutritional programming improves dietary plant protein utilization in zebrafish Danio rerio.

Nutritional Programming (NP) has been shown to counteract the negative effects of dietary plant protein (PP) by introducing PP at an early age towards enhancement of PP utilization during later life stages. This study explored the effect of NP and its induction time on growth, expression of appetite-stimulating hormones, and any morphological changes in the gut possibly responsible for improved dietary PP utilization. At 3 days post-hatch (dph) zebrafish were distributed into 12 (3 L) tanks, 100 larvae per tank. This study included four groups: 1) The control (NP-FM) group received fishmeal (FM)-based diet from 13–36 dph and was challenged with PP-based diet during 36–66 dph; 2) The NP-PP group received NP with dietary PP in larval stage via live food enrichment during 3–13 dph followed by FM diet during 13–36 dph and PP diet during 36–66 dph; 3) The T-NP group received NP between 13–23 dph through PP diet followed by FM diet during 23–36 dph and PP diet during 36–66 dph; and 4) The PP group received PP diet from 13–66 dph. During the PP challenge the T-NP group achieved the highest weight gain compared to control and PP. Ghrelin expression in the brain was higher in T-NP compared to NP-FM and NP-PP, while in the gut it was reduced in both NP-PP and T-NP groups. Cholecystokinin expression showed an opposite trend to ghrelin. The brain neuropeptide Y expression was lower in NP-PP compared to PP but not different with NP-FM and T-NP groups. The highest villus length to width ratio in the middle intestine was found in T-NP compared to all other groups. The study suggests that NP induced during juvenile stages improves zebrafish growth and affects digestive hormone regulation and morphology of the intestinal lining–possible mechanisms behind the improved PP utilization in pre-adult zebrafish stages.

Биологическая роль и клиническое значение нейропептидов в педиатрии: пептид YY и грелин

The increasing prevalence of alimentary obesity necessitates the search for its causes. In addition to eating disorders, other factors were found to affect lipid metabolism, including genetic predisposition, adipose tissue hormones, neurohormones, and digestive tract hormones regulating hunger and satiety, such as peptide YY (PYY) and ghrelin. This literature review focuses on these biologically active substances and their physiological and pathophysiological role. Key words: obesity, peptide, ghrelin

In silico prediction reveals the existence of potential bioactive neuropeptides produced by the human gut microbiota

This work reports on a large-scale potential neuropeptide activity screening in human gut microbiomes deposited in public databases. In our experimental approach, the sequences of the bioactive peptides collected in the MAHMI database, mainly predicted as immunomodulatory or antitumoral, were crossed with those of the neuroactive/digestive peptides. From 91,325,790 potential bioactive peptides, only 581 returned a match when crossed against the 5949 neuroactive peptides from the NeuroPep database and the 15 digestive hormones. Relevant bacterial taxa, such as Ruminococcus sp., Clostridium sp. were found among the main producers of the matching sequences, and many of the matches corresponded to adiponectin and the hormone produced by adipocites, which is involved in glucose homeostasis. These results show, for the first time, the presence of potentially bioactive peptides produced by gut microbiota members over the nervous cells, most notably, peptides with already predicted immunomodulatory or anti-inflammatory activity. Classical (Lactobacillus sp.) and next-generation (Faecalibacterium sp.) probiotics are shown to produce these peptides, which are proposed as a potential mechanism of action of psychobiotics. Our previous experimental results showed that many of these peptides were active when incubated with immune cells, such as dendritic cells, so their effect over the nervous system innervating the gut mucosa holds significant potential and should be explored.

The effects of ghrelin on sleep, appetite, and memory, and its possible role in depression: A review of the literature

ObjectivesGhrelin is an orexigenic digestive hormone that plays a role in sleep and memory. Our work aims is to synthesize the effects of ghrelin on appetite, sleep and memory, and also to evidence its role in depressive disorders. MethodsA systematic search was carried out on PubMed with no time boundaries. The following MeSH terms were used: ghrelin AND (appetite regulation OR obesity), (sleep wake disorders OR sleep) (memory OR cognition disorders) (depression OR depressive disorder OR mood disorder). ResultsGhrelin triggers appetite and alters meal patterns by making them longer and richer. This can lead to pathologies, obesity and insulin-resistance. Ghrelin seems to have a favourable effect on sleep in human beings. It tends to make sleep more efficacious and better quality. Finally, it seems to have an effect on synaptic plasticity in the zones involved in memory and it has been shown to improve memory capacity in rodents. Regarding depression, the administration of ghrelin leads to an anti-depressive effect in animals and in humans. Conversely, post anti-depressant ghrelin titrations have generally shown a decrease in ghrelin levels. Resistant patients seem to retain high levels. Finally, the seriousness of depression could be related to ghrelin levels. ConclusionGhrelin plays a probable part in depression, especially for particular endophenotypes. A better understanding of ghrelin in depression could potentially help to optimize future therapeutic treatments.

Food Effect on Oral Bioavailability: Old and New Questions.

Food Effect on Oral Bioavailability: Old and New Questions.

Changes in Metabolic Hormones in Malaysian Young Adults following Helicobacter pylori Eradication.

BackgroundMore than half of the world’s adults carry Helicobacter pylori. The eradication of H. pylori may affect the regulation of human metabolic hormones. The aim of this study was to evaluate the effect of H. pylori eradication on meal-associated changes in appetite-controlled insulinotropic and digestive hormones, and to assess post-eradication changes in body mass index as part of a currently on-going multicentre ESSAY (Eradication Study in Stable Adults/Youths) study.MethodsWe enrolled 29 H. pylori-positive young adult (18–30 year-old) volunteer subjects to evaluate the effect of H. pylori eradication on meal-associated changes on eight gastrointestinal hormones, using a multiplex bead assay. Changes in body mass index and anthropometric measurements were recorded, pre- and post-eradication therapy.ResultsPre-prandial active amylin, total peptide YY (PYY) and pancreatic polypeptide (PP) levels were significantly elevated 12 months post-eradication compared with baseline (n = 18; Wilcoxon's signed rank test, p<0.05). Four of the post-prandial gut metabolic hormones levels (GLP-1, total PYY, active amylin, PP) were significantly higher 12 months post-eradication compared to baseline (n = 18; p<0.05). Following H. pylori eradication, the BMI and anthropometric values did not significantly change.ConclusionsOur study indicates that H. pylori eradication was associated with long-term disturbance in three hormones (active amylin, PP and total PYY) both pre- and post-prandially and one hormone (GLP-1) post-prandially. Longer post-eradication monitoring is needed to investigate the long-term impact of the observed hormonal changes on metabolic homeostasis.

Molecular cloning and tissue distribution of cholecystokinin-1 receptor (CCK-1R) in yellowtail Seriola quinqueradiata and its response to feeding and in vitro CCK treatment

In vertebrates, the peptide cholecystokinin (CCK) is one of the most important neuroregulatory digestive hormones. CCK acts via CCK receptors that are classified into two subtypes, CCK-1 receptor (CCK-1R; formally CCK-A) and CCK-2 receptor (formally CCK-B). In particular, the CCK-1R is involved in digestion and is regulated by CCK. However, very little information is known about CCK-1R in fish. Therefore, we performed molecular cloning of CCK-1R cDNA from the digestive tract of yellowtail Seriola quinqueradiata. Phylogenetic tree analysis showed a high sequence identity between the cloned yellowtail CCK receptor cDNA and CCK-1R, which belongs to the CCK-1R cluster. Furthermore, the expression of yellowtail CCK receptor mRNA was observed in gallbladder, pyloric caeca, and intestines, similarly to CCK-1R mRNA expression in mammals, suggesting that the cloned cDNA is of CCK-1R from yellowtail. In in vivo experiments, the CCK-1R mRNA levels increased in the gallbladder and pyloric caeca after feeding, whereas in vitro, mRNA levels of CCK-1R and digestive enzymes in cultured pyloric caeca increased by the addition of CCK. These results suggest that CCK-1R plays an important role in digestion stimulated by CCK in yellowtail.

Structure of the agonist-bound neurotensin receptor

SummaryNeurotensin (NT) is a 13 amino acid peptide that functions as both a neurotransmitter and a hormone through activation of the neurotensin receptor NTS1, a G protein-coupled receptor (GPCR). In the brain, NT modulates activity of dopaminergic systems, opioid-independent analgesia, and the inhibition of food intake, and in the gut NT regulates a range of digestive processes. Here we present the structure at 2.8 Å resolution of NTS1 in an active-like state, bound to NT8-13, the C terminal portion of NT responsible for agonist-induced activation of the receptor. The peptide agonist binds to NTS1 in an extended conformation nearly perpendicular to the membrane plane with the C-terminus oriented towards the receptor core. Our findings provide the first insight into the binding mode of a peptide agonist to a GPCR and may support the development of non-peptide ligands that could be useful in the treatment of neurological disorders, cancer and obesity.

Snapshot of an activated peptide receptor

Developing therapeutic drugs that target peptide receptors is challenging. The structure of one of these G-protein-coupled receptors, NTS1, activated and bound to a peptide, provides an excellent starting point. See Article p.508 Neurotensin is a short peptide that can act as a neurotransmitter, a digestive hormone, and a regulator of cardiac output and blood pressure. In this manuscript, the authors solve an X-ray crystal structure of the carboxy-terminal portion of neurotensin bound to a rat neurotensin receptor. This is the first structure of a member of the beta group of class A G-protein-coupled receptors (GPCRs), and the first published structure of a GPCR bound to a peptide agonist. This structure should facilitate the development of non-peptide drugs that could be used to treat neurological disorders, cancer and obesity.

Gastric Band Release Rapidly Impacts Eating Behavior, Satiety Hormones and Weight

Purpose: Bariatric surgery can achieve sustained weight loss compared to medical management. Among bariatric surgeries, laparoscopic adjustable gastric banding (LAGB) is less-invasive and potentially reversible. LAGB may decrease BMI through restriction of food intake, behavior changes, satiety and digestive hormone levels. The dramatic reduction of appetite observed with LAGB can be ameliorated if the band is underfilled. This effect has not been well evaluated in terms of patient behavior and hormonal changes. Our aim was to assess outcomes related to eating behavior, insulinotropic hormones, and weight change before and after temporary gastric band release. Methods: Adults ≥ 18 yeaars of age who previously underwent LAGB and achieved successful weight loss were enrolled. All patients underwent standardized evaluation including anthropometric measurements and completion of the Three-Factor Eating Questionnaire (TEFQ-R18) before and after a period of 14 days during which the band was completely loosened. At baseline and follow-up, blood was collected after an overnight fast and 1h after a standard high protein meal, and levels of insulinotropic hormones determined. Results: The mean age of the study cohort (9 women and 6 men) was 42 ±14 years with mean pre-band adjustment BMI of 32.9 ± 5.6 and mean waist circumference of 40 ± 7 inches. All patients had >30% percent reduction in weight within 12-months of the LAGB and demonstrated a lower degree but continued weight loss in the 6-months before study enrollment. Compared to baseline values for the TEFQ-R18, within 2-weeks of loosening the band, cognitive restraint was reduced (11.2 ± 3 vs. 10.4 ± 4), while there was a significant increase in both disinhibition (6.4 ± 3 vs. 9.4 ± 3, p=0.004) and hunger scores (4.1 ± 3 vs. 8.0 ± 3, p=0.004). Compared to baseline, at follow-up insulin output in response to a meal showed a downward trend [Median (IQR) 1,110 (728-1,332) vs. 621 (375-1,325) pg/ml; p=0.21] while leptin was significantly elevated [10,400 (6,030-11,350) vs. 13,700 (10,500-43,900) pg/ml; p=0.001]. Consistent with these findings BMI significantly increased (32.9 ± 5.6 vs. 34.5 ± 5.6, p=0.001) along with waist size (40 ± 7 vs 42 ± 6, p=0.003). The amount of weight regained within two weeks, returned the cohort to the weight loss level noted at the 12-month post LAGB time point. Conclusion: LAGB adjustment continues to impact eating behavior, satiety hormones, and body weight beyond the initial 12-months following placement. Complete loosening of the LAGB can result in rapid changes in eating behavior, insulinotropic hormones, and significant changes in BMI. Careful adjustment of the band is necessary for continued maintenance of weight loss.

Body weight reducing effects of crude caseinomacropeptide prepared from Na-caseinate

Caseinomacropeptide (CMP) from casein has been reported to have several physiological functions. The crude CMP produced from Na-caseinate using a commercial renneting enzyme was used in this study. The renneting enzyme hydrolyzed most of Na-caseinate to release crude CMP within 1 h. The crude CMP prepared from Nacaseinate by renneting enzyme and ultrafiltration was relatively pure according to SDS-gel electrophoresis and amino acid composition, and existed as a dimmer. The administration of crude CMP with a high fat diet in the high fat+CMP group reduced food efficiency ratio to the level of the control group. This result indicates that the crude CMP may be involved in inhibitory actions over digestive functions. Food intake and body weight gain in the high fat+CMP group were reduced compared to the high fat group by 10.9 and 21.5%, respectively, indicating that the crude CMP may lower an efficacy of digestive functions in gastrointestinal cells as well as suppress satiety by controlling a secretion of digestive hormones.

M2053 Spectral Analysis of the Dominant Frequency of Upper GI Motility-Assessment of Invasive Versus Non-Invasive Techniques

Segments of the rat GI tract were everted and subjected to a short pronase digestion and elutriation to obtain purified mucosal epithelial cells. RNA was isolated, labelled for microarray hybridization, and comparative whole rat genome expression analysis performed.Results: 12% of all annotated genes show segment specific enrichment. The gastric (>3000 genes) and ileal (519 genes) mucosa show the most diverse expression profile. (a) Stomach: The gastric mucosa expresses the machinery for acid secretion, digestive enzyme release and hormone release by endocrine cells. Associated with acid secretion is a specific set of K+, Cl-, and bicarbonate channels. Novel is a pathway for glucose and fatty acid sensing, iodide and glutamate uptake, and taurine synthesis. Specific sets of transcription factors control epithelial (Barx1, Runx) and enteroendocrine (FoxA2/N4) cell differentiation. (b) Small Bowel: This epithelium expresses genes encoding a unique fructose/glucose uptake and utilization mechanism. Several endocrine signals for gastric function are present. The upper portion expresses genes for iron uptake, bicarbonate secretion, pH homeostasis and detoxification of food contents. Epithelial differentiation is transcriptionally controlled by Meis2/ Pdx1 and Onecut 2. Expression of digestive enzymes, lipid/bile acid uptake and utilization increases in the distal small bowel. The ileum is also involved in innate and acquired immune defence, regulation of motility and electrolyte and water re-absorption. Transcriptional regulation of enterocyte and goblet cell differentiation is mainly controlled by increasing expression of Cdx1 and 2. (c) Colon: This epithelium is mainly involved in Ca++-, K+, and water re-absorption, short-chain fatty acid uptake and sensing, and innate and acquired immune defence. Epithelial differentiation is controlled by Hox transcription factors in addition to Cdx1/2. Conclusion: This survey of gene expression by the GI tract epithelium reveals unique epithelial properties, providing novel areas of exploration to define the roles of many of the encoded proteins in gut physiology.

Serum somatostatin in early-stage Parkinson’s disease

To compare levels of plasma digestive hormones in patients with and without nausea or vomiting during initial treatment of early-stage Parkinson's disease (PD). This was a 3-week, open-label, randomized study of treatment with an antiparkinson drug in untreated PD patients. We measured the levels of plasma digestive hormones before (baseline) and 3 weeks after administration of an antiparkinson drug. Mean value of serum somatostatin at baseline was significantly increased in PD patients compared with the control group (P < 0.01). Serum somatostatin levels were significantly increased after treatment in subjects who experienced nausea or vomiting (P < 0.01). However, significant increase in serum somatostatin levels after treatment was not observed in PD patients without nausea or vomitting. Serum somatostatin in early-stage PD patients before treatment was increased compared with healthy subjects. The nausea and vomiting induced by antiparkinson drugs may be related to uncontrolled somatostatin secretion through central vagus nerve dysfunction.

T1982 Alcohol Stimulates Activation of Snail, Epidermal Growth Factor Receptor Signaling, and Markers of Epithelial-Mesenchymal Transition in Colon and Breast Cancer and Normal Intestinal Epithelial Cells

Background: Obesity is associated with an increased risk of colorectal cancer. Derangements in gut hormones that regulate energy balance and metabolism may influence epithelial growth. The aim was to evaluate insulinotropic and digestive hormones in an average risk colorectal cancer (CRC) screening population. Methods: Consecutive patients referred for CRC screening at a municipal hospital were enrolled, and a detailed medical evaluation including height and weight was obtained prior to colonoscopy. A total of 15cc of blood was collected and plasma concentrations of total amylin, acylated ghrelin, glucose-dependent insulinotropic peptide (GIP), active glucagon-like peptide-1 (GLP-1), insulin, leptin, pancreatic polypeptide (PP), and peptide YY (PYY) were measured using a multiplex immunoassay. Based on histologic confirmation of colonoscopic findings, cases (CAs) were defined as individuals with any adenomas regardless of size, including those with villous histology, high-grade dysplasia, or adenocarcinoma. Controls (COs) were selected from individuals without any colonic lesions and matched to the cases based on age, gender, ethnicity, and body mass index. Results: A total of 108 CAs, 56 men and 52 women, (mean age 61 ± 7 years, BMI 26.7 ± 4) were enrolled and matched to 108 COs. The study cohort was composed of Hispanics (58%), Asians (25%), African Americans (14%), and Caucasians (3%). Reflecting fat stores, plasma leptin was significantly correlated to BMI in CAs (r=0.92, p<0.001) and COs (r=0.77, p<0.001). Plasma level of active GLP-1 was markedly elevated in CAs (1130 pg/ml, IQR 548-1610) compared to COs (315 pg/ml, IQR 171-789); p<0.001. Similarly total amylin was significantly elevated in CAs (median 496 pg/ml, IQR 135-754) compared to COs (median 214 pg/ml, IQR 75-471); p<0.001. Although the prevalence of diabetes did not differ between the two groups (25% vs 21%), plasma insulin was lower in CAs (380 pg/ml, IQR 180-566) compared to COs (455 pg/ml, IQR 331-621); p<0.001. Additionally, among women active ghrelin was significantly elevated in CAs (31 pg/ml, IQR 19-49) compared to COs (16 pg/ml, IQR 8-39); p=0.005. Among men, leptin was also significantly elevated in CAs (4235 pg/ml, IQR 1992-6617) compared to COs (2710 pg/ml, IQR 12255245); p=0.047. Conclusions: In this ethnically diverse average risk CRC screening population insulinotropic peptides differentiated individuals with and without colon pathology independent of diabetes. The association of leptin and ghrelin with colon adenomas differs according to gender. Further studies are warranted on the role of gut hormones involved in energy homeostasis and colon cancer development.